Coram Healthcare Corp (NYSE:CRH) Institutional Investor Sentiment Is 1.45

CRH plc (NYSE:CRH) Logo

Sentiment for Coram Healthcare Corp (NYSE:CRH)

Coram Healthcare Corp (NYSE:CRH) institutional sentiment decreased to 1.45 in 2018 Q2. Its down -0.15, from 1.6 in 2018Q1. The ratio has dropped, as 64 investment managers opened new and increased stock positions, while 44 sold and decreased positions in Coram Healthcare Corp. The investment managers in our partner’s database now own: 37.54 million shares, up from 36.17 million shares in 2018Q1. Also, the number of investment managers holding Coram Healthcare Corp in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 10 Reduced: 34 Increased: 48 New Position: 16.

CRH plc, through its subsidiaries, manufactures and distributes building materials. The company has market cap of $22.49 billion. The firm operates through seven divisions: Europe Heavyside, Europe Lightside, Europe Distribution, Americas Materials, Americas Products, Americas Distribution, and Asia. It has a 6.71 P/E ratio. The firm makes and supplies cement, aggregates, ready-mixed and precast concrete, concrete landscaping, and asphalt products; and construction accessories, shutters and awnings, and fencing and composite access chambers.

The stock increased 0.95% or $0.26 during the last trading session, reaching $27.74. About 402,616 shares traded. CRH plc (NYSE:CRH) has declined 9.53% since November 26, 2017 and is downtrending. It has underperformed by 25.15% the S&P500.

Cutter & Co Brokerage Inc. holds 1.01% of its portfolio in CRH plc for 74,200 shares. Renaissance Group Llc owns 509,502 shares or 0.64% of their US portfolio. Moreover, Gmt Capital Corp has 0.63% invested in the company for 738,600 shares. The Illinois-based Thomas White International Ltd has invested 0.59% in the stock. Todd Asset Management Llc, a Kentucky-based fund reported 460,451 shares.

CRH plc (NYSE:CRH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.